Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders

British Journal of Haematology

Volumn 149, Issue 3, 2010, Pages 334-351

  Raja, Karthick R M ^a   Kovarova, Lucie ^a,b   Hajek, Roman ^a,b  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Malignant plasma cells; MGUS; MM; Myeloma precursor cells; Plasma cell proliferative disorders

Indexed keywords

5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BELINOSTAT; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CD19 ANTIGEN; CD20 ANTIGEN; CD200 ANTIGEN; CD27 ANTIGEN; CD28 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CD81 ANTIGEN; CD9 ANTIGEN; CHEMOKINE RECEPTOR ANTAGONIST; DEXAMETHASONE; DOXORUBICIN; GLUCOCORTICOID; HERMES ANTIGEN; LENALIDOMIDE; MELPHALAN; MLN 3897; RESVERATROL; RITUXIMAB; STEM CELL FACTOR RECEPTOR; SYNDECAN 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

AMYLOIDOSIS; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE DISEASE; CANCER RESISTANCE; CANCER SURVIVAL; CLONAL VARIATION; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DRUG MEGADOSE; DRUG RESPONSE; DRUG TARGETING; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; INTERMETHOD COMPARISON; MARGINAL ZONE LYMPHOMA; MINIMAL RESIDUAL DISEASE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NONHUMAN; PLASMA CELL LEUKEMIA; PLASMACYTOMA; PLASMACYTOSIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; WALDENSTROEM MACROGLOBULINEMIA;

ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; PLASMA CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 77950799458     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08121.x     Document Type: Review

References (170)

1. Agematsu, K., Nagumo, H., Oguchi, Y., Nakazawa, T., Fukushima, K., Yasui, K., Ito, S., Kobata, T., Morimoto, C. Komiyama, A. (1998) Generation of plasma cells from peripheral blood memory B cells: synergistic effect of interleukin-10 and CD27/CD70 interaction. Blood, 91, 173 180. (Pubitemid 28018742)
2. Almeida, J., Orfao, A., Ocqueteau, M., Mateo, G., Corral, M., Caballero, M.D., Blade, J., Moro, M.J., Hernandez, J. San Miguel, J.F. (1999) High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in MM. British Journal of Haematology, 107, 121 131. (Pubitemid 29500817)
3. Ashmann, E.J., Lokhorst, H.M., Dekker, A.W. Bloem, A.C. (1992) Lymphocyte function-associated antigen 1 expression on plasma cells correlates with tumor growth in MM. Blood, 79, 2068 2075.
4. Asosingh, K., De Raeve, H., Van Riet, I., Van Camp, B. Vanderkerken, K. (2003) MM tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis. Blood, 101, 3136 3141. (Pubitemid 36858007)
5. Asosingh, K., De Raeve, H., Menu, E., Van Riet, I., Van Marck, E., Van Camp, B. Vanderkerken, K. (2004) Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity. Blood, 103, 3131 3137. (Pubitemid 38451691)
6. Barille, S., Collette, M., Bataille, R. Amiot, M. (1995) Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Blood, 86, 3151 3159.
7. Bataille, R., Chappard, D. Basle, M. (1995) Excessive bone resorption in human plasmacytomas: direct induction by tumour cells in vivo. British Journal of Haematology, 90, 721 724.
8. Bataille, R., Robillard, N., Pellat-Deceunynck, C. Amiot, M. (2003) A cellular model for myeloma cell growth and maturation based on an intraclonal CD45 hierarchy. Immunological Reviews, 194, 105 111. (Pubitemid 36886432)
9. Bataille, R., Robillard, N., Avet-Loiseau, H., Harousseau, J.L. Moreau, P. (2005) CD221(IGF-1R) is aberrantly expressed in MM, in relation to disease severity. Haematologica, 90, 706 707. (Pubitemid 40780900)
10. Bataille, R., Jego, G., Robillard, N., Barille-Nion, S., Harousseau, J.L., Moreau, P., Amiot, M. Pellat-Deceunynck, C. (2006) The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. Haematologica, 91, 1234 1240. (Pubitemid 44408434)
11. Bataille, R., Pellat-Deceunynck, C., Robillard, N., Avet-Loiseau, H., Harousseau, J.L. Moreau, P. (2008) CD117 (c-kit) is aberrantly expressed in a subset of MGUS and MM with unexpectedly good prognosis. Leukemia Research, 32, 379 382. (Pubitemid 351295923)
12. Bergsagel, P.L., Smith, A.M., Szczepek, A., Mant, M.J., Belch, A.R. Pilarski, L.M. (1995) In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. Blood, 85, 436 447.
13. Billadeau, D., Ahmann, G., Greipp, P. Van Ness, B. (1993) The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. Journal of Experimental Medicine, 178, 1023 1031. (Pubitemid 23260440)
14. Billadeau, D., Van Ness, B., Kimlinger, T., Kyle, R.A., Therneau, T.M., Greipp, P.R. Witzig, T.E. (1996) Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering MM, and active myeloma. Blood, 88, 289 296. (Pubitemid 26230698)
15. Bladé, J., Samson, D., Reece, D., Apperley, J., Björkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British Journal of Haematology, 102, 1115 1123.
16. Blaheta, R.A., Hundemer, M., Mayer, G., Vogel, J.U., Kornhuber, B., Cinatl, J., Markus, B.H., Driever, P.H. Cinatl, Jr., J. (2002) Expression level of neural cell adhesion molecule (NCAM) inversely correlates with the ability of neuroblastoma cells to adhere to endothelium in vitro. Cell Communication and Adhesion, 9, 131 147. (Pubitemid 36024631)
17. Blaheta, R.A., Beecken, W.D., Engl, T., Jonas, D., Oppermann, E., Hundemer, M., Doerr, H.W., Scholz, M. Cinatl, J. (2004) Human cytomegalovirus infection of tumor cells downregulates NCAM (CD56): a novel mechanism for virus-induced tumor invasiveness. Neoplasia, 6, 323 331. (Pubitemid 38924847)
18. Boccadoro, M., Omede, P., Massaia, M., Dianzani, U., Pioppo, P., Battaglio, S., Meregalli, M. Pileri, A. (1988) Human myeloma: several subsets of circulating lymphocytes express plasma cell-associated antigens. European Journal of Haematology, 40, 299 304.
19. Camerini, D., Walz, G., Loenen, W.A., Borst, J. Seed, B. (1991) The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family. Journal of Immunology, 147, 3165 3169.
20. Cha, C.H., Park, C.J., Huh, J.R., Chi, H.S., Suh, C.W. Kang, Y.K. (2007) Significantly better prognosis for patients with primary plasma cell leukemia than for patients with secondary plasma cell leukaemia. Acta Haematologica, 118, 178 182.
21. Chen, B.J. Epstein, J. (1996) Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B cells. Blood, 87, 1972 1976. (Pubitemid 26068913)
22. Chilosi, M., Adami, F., Lestani, M., Montagna, L., Cimarosto, L., Semenzato, G., Pizzolo, G. Menestrina, F. (1999) CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies. Modern Pathology, 12, 1101 1106. (Pubitemid 30033542)
23. Conway, E.J., Wen, J., Feng, Y., Mo, A., Huang, W.T., Keever-Taylor, C.A., Hari, P., Vesole, D.H. Chang, C.C. (2009) Phenotyping studies of clonotypic B lymphocytes from patients with multiple myeloma by flow cytometry. Archives of Pathology & Laboratory Medicine, 133, 1594 1599.
24. Crossin, K.L. Krushel, L.A. (2000) Cellular signaling by neural cell adhesion molecules of the immunoglobulin superfamily. Developmental dynamics, 218, 260 279. (Pubitemid 30349639)
25. Cunningham, B.A., Hemperly, J.J., Murray, B.A., Prediger, E.A., Brackenbury, R. Edelman, G.M. (1987) Neural cell adhesion molecule: structure, immunoglobulin-like domains, cell surface modulation, and alternative RNA splicing. Science, 236, 799 806.
26. De Grendele, H.C., Estess, P. Siegelman, M.H. (1997) Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science, 278, 672 675. (Pubitemid 27464963)
27. De Vos, J., Hose, D., Reme, T., Tarte, K., Moreaux, J., Mahtouk, K., Jourdan, M., Goldschmidt, H., Rossi, J.F., Cremer, F.W. Klein, B. (2006) Microarray-based understanding of normal and malignant plasma cells. Immunological Reviews, 210, 86 104.
28. Dimopoulos, M.A., Palumbo, A., Delasalle, K.B. Alexanian, R. (1994) Primary plasma cell leukaemia. British Journal of Haematology, 88, 754 759. (Pubitemid 24375790)
29. Drach, J., Gattringer, C. Huber, H. (1991) Expression of the neural cell adhesion molecule (CD56) by human myeloma cells. Clinical and Experimental Immunology, 83, 418 422.
30. Driel, M.V., Gunthert, U., Stauder, R., Joling, P., Lokhorst, H.M. Bloem, A.C. (1998) CD44 isoforms distinguish between BM plasma cells from normal individuals and patients with MM at different stages of disease. Leukemia, 12, 1821 1828. (Pubitemid 28502504)
31. Durie, B.G., Harousseau, J.L., Miguel, J.S., Blade, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Cavo, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G. Rajkumar, S.V. International Myeloma Working Group (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, 1467 1473. (Pubitemid 44264086)
32. Edelman, G.M. Crossin, K.L. (1991) Cell adhesion molecules: implications for a molecular histology. Annual Review of Biochemistry, 60, 155 190.
33. Edvardsen, K., Chen, W., Rucklidge, G., Walsh, F.S., Obrink, B. Bock, E. (1993) Transmembrane neural cell-adhesion molecule (NCAM), but not glycosyl phosphatidylinositol-anchored NCAM, down-regulates secretion of matrix metalloproteinases. Proceedings of the National Academy of Sciences of the United States of America, 90, 11463 11467. (Pubitemid 24008659)
34. Ely, S.A. Knowles, D.M. (2002) Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. American Journal of Pathology, 160, 1293 1299.
35. Esteve, F.R. Roodman, G.D. (2007) Pathophysiology of myeloma bone disease. Best Practice & Research. Clinical Haematology, 20, 613 624.
36. Feyler, S., O'Connor, J.M.S., Rawstron, C.A., Chezhian, S., Ross, M.F., Pratt, G., Drayson, T.G., Cook, G.A.J. Owen, G.R. (2008) IgM myeloma: a rare entity characterized by a CD20- CD56- CD117- immunophenotype and the t(11:14). British Journal of Haematology, 140, 547 551.
37. Freeman, S.D., Kelm, S., Barber, E.K. Croker, P.R. (1995) Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood, 85, 2005 2012.
38. García-Sanz, R., Orfão, A., González, M., Tabernero, M.D., Bladé, J., Moro, M.J., Fernández-Calvo, J., Sanz, M.A., Pérez-Simón, J.A., Rasillo, A. San Miguel, J.F. (1999) Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood, 93, 1032 1037. (Pubitemid 29067869)
39. Gertz, M.A., Kyle, R.A. Greipp, P.R. (1989) The plasma cell labeling index: a valuable tool in primary systemic amyloidosis. Blood, 74, 1108 1111.
40. Ghosh, N. Matsui, W. (2009) Cancer stem cells in multiple myeloma. Cancer Letters, 277, 1 7.
41. Giuliani, N., Rizzoli, V. Roodman, G.D. (2006) MM bone disease: pathophysiology of osteoblast inhibition. Blood, 108, 3992 3996. (Pubitemid 44913267)
42. Guikema, J.E., Hovenga, S., Vellenga, E., Conradie, J.J., Abdulahad, W.H., Bekkema, R., Smit, J.W., Zhan, F., Shaughnessy, Jr., J. Bos, N.A. (2003) CD27 is heterogeneously expressed in MM: low CD27 expression in patients with high-risk disease. British Journal of Haematology, 121, 36 43. (Pubitemid 36461265)
43. Guinan, E.C., Gribben, J.G., Boussiotis, V.A., Freeman, G.J. Nadler, L.M. (1994) Pivotal role of the B7: CD28 pathway in transplantation tolerance and tumor immunity. Blood, 84, 3261 3282.
44. Gunthert, U. (1993) CD44: a multitude of isoforms with diverse functions. Current Topics in Microbiology and Immunology, 184, 47 63. (Pubitemid 24014176)
45. Haghighi, B., Yanagihara, R. Cornbleet, P.J. (1998) IgM myeloma: case report with immunophenotypic profile. American Journal of Hematology, 59, 302 308. (Pubitemid 28543619)
46. Hamburger, A.W. Salmon, S.E. (1977) Primary bioassay of human tumor stem cells. Science, 197, 461 463.
47. Hamilton, M.S., Ball, J., Bromidge, E. Franklin, I.M. (1991) Surface antigen expression of human neoplastic plasma cells includesmolecules associated with lymphocyte recirculation and adhesion. British Journal of Haematology, 78, 60 65.
48. Harada, H., Kawano, M.M., Huang, N., Harada, Y., Iwato, K., Tanabe, O., Tanaka, H., Sakai, A., Asaoku, H. Kuramoto, A. (1993) Phenotypic difference of normal plasma cells from mature myeloma cells. Blood, 81, 2658 2663. (Pubitemid 23147570)
49. Heider, K.H., Kuthan, H., Stehle, G. Munzert, G. (2004) CD44v6: a target for antibody-based cancer therapy. Cancer Immunology, Immunotherapy, 53, 567 579. (Pubitemid 38858330)
50. Hermiston, M.L., Zhen, X. Weiss, A. (2002) CD45: a critical regulator of signaling thresholds in immune cells. Annual Review of Immunology, 21, 107 137. (Pubitemid 37174528)
51. Hintzen, R.Q., de Jong, R., Lens, S.M. van Lier, R.A. (1994) CD27: marker and mediator of T-cell activation. Immunology Today, 15, 307 311. (Pubitemid 24231744)
52. Hundemer, M., Klein, U., Hose, D., Raab, M.S., Cremer, F.W., Jauch, A., Benner, A., Heiss, C., Moos, M., Ho, A.D. Goldschmidt, H. (2007) Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14). Bone Marrow Transplantation, 40, 1033 1037. (Pubitemid 350142555)
53. Hussong, J.W., Perkins, S.L., Schnitzer, B., Hargreaves, H. Frizzera, G. (1999) Extramedullary plasmacytoma. A form of marginal zone cell lymphoma? American Journal of Clinical Pathology, 111, 111 116.
54. International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, MM and related disorders: a report of the International Myeloma Working Group. British Journal of Haematology, 121, 749 757.
55. Jacquot, S., Kobata, T., Iwata, S., Morimoto, C. Schlossman, S.F. (1997) CD154/CD40 and CD70/CD27 interactions have different and sequential functions in T cell-dependent B cell responses. Journal of Immunology, 159, 2652 2657.
56. Jego, G., Robillard, N., Puthier, D., Amiot, M., Accard, F., Pineau, D., Harousseau, J.L., Bataille, R. Pellat-Deceunynck, C. (1999) Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. Blood, 94, 701 712.
57. Jensen, G.S., Mant, M.J., Belch, A.J., Berenson, J.R., Ruether, B.A. Pilarski, L.M. (1991) Selective expression of CD45 isoforms defines CALLA+ monoclonal B-lineage cells in peripheral blood from myeloma patients as late stage B cells. Blood, 78, 711 719.
58. Jensen, G.S., Belch, A.R., Mant, M.J., Ruether, B.A. Pilarski, L.M. (1992) Expression of multiple adhesion molecules on circulating monoclonal B cells in myeloma. Current Topics in Microbiology and Immunology, 182, 187 193.
59. Johnson, P. Glennie, M. (2003) The mechanisms of action of rituximab in the elimination of tumor cells. Seminars in Oncology, 30, 3 8.
60. June, C.H., Bluestone, J.A., Nadler, L.M. Thompson, C.B. (1994) The B7 and CD28 receptor families. Immunology Today, 15, 321 337.
61. Katayama, Y., Sakai, A., Oue, N., Asaoku, H., Otsuki, T., Shiomomura, T., Masuda, R., Hino, N., Takimoto, Y., Imanaka, F., Yasui, W. Kimura, A. (2003) A possible role of the loss of CD27-CD70 interaction in myelomagenesis. British Journal of Haematology, 120, 223 234.
62. Kim, I., Uchiyama, H., Chauhan, D. Anderson, K.C. (1994) Cell surface expression and functional significance of adhesion molecules on human myeloma-derived cell lines. British Journal of Haematology, 87, 483 493.
63. Kimlinger, T. Witzig, T.E. (1997) Expression of the hematopoietic stem cell antigen CD34 on blood and bone marrow monoclonal plasma cells from patients with multiple myeloma. Bone Marrow Transplantation, 19, 553 556.
64. Kiyokawa, N., Kokai, Y., Ishimoto, K., Fujita, H., Fujimoto, J. Hata, J.I. (1990) Characterization of the CALLA (CD10) as an activation molecule on mature human B cells. Clinical Experimental Immunology, 79, 322 327.
65. Kovarova, L., Buresova, I., Buchler, T., Suska, R., Pour, L., Zahradova, L., Penka, M. Hajek, R. (2009) Phenotype of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Neoplasma, 56, 526 532.
66. Kraj, M., Poglod, R., Kopec- Szlezak, J., Sokolowska, U., Woziank, J. Kruk, B. (2004) Intensity of expression of the CD117 antigen (c-kit) on myelomatous plasma cells. Central European Journal of Immunology, 29, 1 9. (Pubitemid 40825785)
67. Kremer, M., Ott, G., Nathrath, M., Specht, K., Stecker, K., Alexiou, C., Quintanilla-Martinez, L. Fend, F. (2005) Primary extramedullary plasmacytoma and MM: phenotypic differences revealed by immunohistochemical analysis. Journal of Pathology, 205, 92 101.
68. Krushel, L.A., Tai, M.H., Cunningham, B.A., Edelman, G.M. Crossin, K.L. (1998) Neural cell adhesion molecule (N-CAM) domains and intracellular signaling pathways involved in the inhibition of astrocyte proliferation. Proceedings of the National Academy of Sciences of the United States of America, 95, 2592 2596.
69. Kucharska-Pulczynska, M., Ellegaard, J. Hokland, P. (1987) Analysis of leucocyte differentiation antigens in blood and bone marrow from patients with Waldenström's macroglobulinemia. British Journal of Haematology, 65, 395 402.
70. Kumar, S., Rajkumar, S.V., Kyle, R.A., Lacy, M.Q., Dispenzieri, A., Fonseca, R., Lust, J.A., Gertz, M.A., Greipp, P.R. Witzig, T.E. (2005a) Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. Journal of Clinical Oncology, 23, 5668 5674.
71. Kumar, S., Rajkumar, S.V., Kimlinger, T., Greipp, P.R. Witzig, T.E. (2005b) CD45 expression by bone marrow plasma cells in MM: clinical and biological correlations. Leukemia, 19, 1466 1470.
72. Kuranda, K., Berthon, C., Dupont, C., Wolowiec, D., Leleu, X., Polakowska, R., Jouy, N. Quesnel, B. (2010) A subpopulation of malignant CD34(+)CD138(+)B7-H1(+) plasma cells is present in multiple myeloma patients. Experimental Hematology, 38, 124 131.
73. Kyle, R.A. (1978) Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. American Journal of Medicine, 64, 814 826.
74. Kyle, R.A. Gertz, M.A. (1995) Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Seminars in Hematology, 32, 45 59.
75. Kyle, R.A. Rajkumar, S.V. (2006) Monoclonal gammopathy of undetermined significance. British Journal of Haematology, 134, 573 589.
76. Kyle, R.A. Rajkumar, S.V. (2009) Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia, 23, 3 9.
77. Kyle, R.A., Linos, A., Beard, C.M., Linke, R.P., Gertz, M.A., O'Fallon, W.M. Kurland, L.T. (1992) Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood, 79, 1817 1822.
78. Kyle, R.A., Therneau, T.M., Rajkumar, S.V., Offord, J.R., Larson, D.R., Plevak, M.F. Melton, L.J. (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. New England Journal of Medicine, 346, 564 569.
79. Kyle, R.A., Therneau, T.M., Rajkumar, S.V., Remstein, E.D., Offord, J.R., Larson, D.R., Plevak, M.F. Melton, III., L.J. (2003) Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood, 102, 3759 3764.
80. Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M.A. Dick, J.E. (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature, 367, 645 648.
81. Leo, R., Boeker, M., Peest, D., Hein, R., Bartl, R., Gessner, J.E., Selbach, J., Wacker, G. Deicher, H. (1992) Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells. Annals of Hematology, 64, 132 139.
82. Liebisch, P., Eppinger, S., Schopflin, C., Stehle, G., Munzert, G., Döhner, H. Schmid, M. (2005) CD44v6, a target for novel antibody treatment approaches, is frequently expressed in MM and associated with deletion of chromosome arm 13q. Haematologica, 90, 489 493.
83. Linsley, P.S. Ledbetter, J.A. (1993) The role of the CD28 receptor during cell responses to antigen. Annual Review of Immunology, 11, 191 212.
84. Lioznov, M., Badbaran, A., Fehse, B., Bacher, U., Zander, A.R. Kroger, N.M. (2008) Monitoring of minimal residual disease in multiple myeloma after allo-SCT: flow cytometry vs. PCR-based techniques. Bone Marrow Transplantation, 41, 913 916.
85. Liu, J., Hamrouni, A., Wolowiec, D., Coiteux, V., Kuliczkowski, K., Hetuin, D., Saudemont, A. Quesnel, B. (2007) Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-(gamma) and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood, 110, 296 304.
86. Lokhorst, H.M., Lamme, T., de Smet, M., Klein, S., de Weger, R.A., van Oers, R. Bloem, A.C. (1994) Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood, 84, 2269 2277.
87. Lovell, R., Dunn, J.A., Begum, G., Barth, N.J., Plant, T., Moss, P.A., Drayson, M.T. Pratt, G. On behalf of Working Party on Leukaemia in Adults of the National Cancer Research Institute Haematological Oncology Clinical Studies Group (2005) Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival. British Journal of Haematology, 130, 542 548.
88. Mahmoud, M.S., Fujii, R., Ishikawa, H. Kawano, M.M. (1999) Enforced CD19 expression leads to growth inhibition and reduced tumorigenicity. Blood, 94, 3551 3558.
89. Martin, P., Santon, A. Bellas, C. (2004) Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between MM, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis. Histopathology, 44, 375 380.
90. Mateo, G., Castellanos, M., Rasillo, A., Gutiérrez, N.C., Montalbán, M.A., Martín, M.L., Hernández, J.M., López-Berges, M.C., Montejano, L., Bladé, J., Mateos, M.V., Sureda, A., de la Rubia, J., Díaz-Mediavilla, J., Pandiella, A., Lahuerta, J.J., Orfao, A. San Miguel, J.F. (2005) Genetic abnormalities and patterns of antigenic expression in MM. Clinical Cancer Research, 11, 3661 3667.
91. Mateo, G., Montalban, M.A., Vidriales, M.B., Lahuerta, J.J., Mateos, M.V., Gutiérrez, N., Rosiñol, L., Montejano, L., Bladé, J., Martínez, R., de la Rubia, J., Diaz-Mediavilla, J., Sureda, A., Ribera, J.M., Ojanguren, J.M., de Arriba, F., Palomera, L., Terol, M.J., Orfao, A. San Miguel, J.F. (2008) Prognostic value of immunophenotyping in MM: a study by the PETHAMA/GEM cooperative study groups on patients uniformly treated with high dose theraphy. Journal of Clinical Oncology, 26, 2737 2743.
92. Mateos, M.V., López-Corral, L., Hernández, M.T., de la Rubia, J., Lahuerta, J.J., Giraldo, P., Bargay, J., Rosiñol, L., Oriol, A., García-Laraña, J., Palomera, L., de Arriba, F., Prosper, F., Martino, M., Teruel, A.I., Hernandez, J., Esteves, G., Mariz, M., Alegre, A., Guzmán, J.L., Quintana, N., Garcia, J.L. San-Miguel, J.F. (2009) Multicenter, randomized, open-label, phase III trial of lenalidomide- dexamethasone (Len/dex) vs therapeutic abstention in smoldering multiple myeloma at high risk of progression to symptomatic MM: results of the first interim analysis. Blood, 114, abstract no: 614.
93. Matsuda, M., Gono, T., Shimojima, Y., Sakashita, K., Koike, K. Ikeda, S. (2003) Evaluation of intensive chemotherapy in AL amyloidosis: usefulness of flow cytometric analysis of plasma cells in bone marrow. Amyloid: The International Journal of Experimental and Clinical Investigation: The Official Journal of the International Society of Amyloidosis, 10, 250 256.
94. Matsui, W., Huff, C.A., Wang, Q., Malehorn, M.T., Barber, J., Tanhehco, Y., Smith, B.D., Civin, C.I. Jones, R.J. (2004) Characterization of clonogenic MM cells. Blood, 103, 2332 2336.
95. Matsui, W., Wang, Q., Barber, J.P., Brennan, S., Smith, B.D., Borrello, I., McNiece, I., Lin, L., Ambinder, R.F., Peacock, C., Watkins, D.N., Huff, C.A. Jones, R.J. (2008) Clonogenic MM progenitors, stem cell properties, and drug resistance. Cancer Research, 68, 190 197.
96. Maurer, D., Holter, W., Majdic, O., Fischer, G.F. Knapp, W. (1990) CD27 expression by a distinct subpopulation of human B lymphocytes. European Journal of Immunology, 20, 2679 2684.
97. Merlini, G. Bellotti, V. (2003) Molecular mechanisms of amyloidosis. New England Journal of Medicine, 349, 583 596.
98. Miettinen, M. Lasota, J. (2005) KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Applied Immunohistochemistry & Molecular Morphology, 13, 205 220.
99. Miyake, K., Medina, K.L., Hayashi, S.I., Ono, S., Hamaoka, T. Kincade, P.W. (1990) Monoclonal antibodies to Pgp-1/CD44 block lympho-hemopoiesis in long-term bone marrow cultures. Journal of Experimental Medicine, 171, 477 488.
100. Moreau, P., Robillard, N., Avet-Loiseau, H., Pineau, D., Morineau, N., Milpied, N., Harousseau, J.L. Bataille, R. (2004) Patients with CD45 negative MM receiving high-dose therapy have a shorter survival than those with CD45 positive MM. Haematologica, 89, 547 551.
101. Moreaux, J., Hose, D., Reme, T., Jourdan, E., Hundemer, M., Legouffe, E., Moine, P., Bourin, P., Moos, M., Corre, J., Möhler, T., De Vos, J., Rossi, J.F., Goldschmidt, H. Klein, B. (2006) CD200 is a new prognostic factor in multiple myeloma. Blood, 108, 4194 4197.
102. Morice, W.G., Hanson, C.A., Kumar, S., Frederick, L.A., Lesnick, C.E. Greipp, P.R. (2007) Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders. Leukemia, 21, 2043 2046.
103. Morice, W.G., Chen, D., Kurtin, P.J., Hanson, C.A. McPhail, E.D. (2009) Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström's macroglobulinemia. Modern Pathology, 22, 807 816.
104. Noel, P. Kyle, R.A. (1987) Plasma cell leukemia: an evaluation of response to therapy. American Journal of Medicine, 83, 1062 1068.
105. O'Connell, F.P., Pinkus, J.L. Pinkus, G.S. (2004) CD138 (Syndecan-1), a plasma cell marker. American Journal of Clinical Pathology, 121, 254 263.
106. Ocqueteau, M., Orfao, A., Garcia-Sanz, R., Almeida, J., Gonzalez, M. San Miguel, J.F. (1996) Expression of the CD117 antigen (c-kit) on normal and myelomatous plasma cells. British Journal of Haematology, 95, 489 493.
107. Ocqueteau, M., Orfao, A., Almeida, J., Blade, J., González, M., García-Sanz, R., López-Berges, C., Moro, M.J., Hernández, J., Escribano, L., Caballero, D., Rozman, M. San Miguel, J.F. (1998) Immunophenotypic Characterization of Plasma cells from Monoclonal Gammopathy of Undetermined significance Patients. American Journal of Pathology, 152, 1655 1665.
108. Olteanu, H., Wang, H.Y., Chen, W., McKenna, R.W. Karandikar, N.J. (2008) Immunophenotypic studies of monoclonal gammopathy of undetermined significance. BMC Clinical Pathology, 8, 1 9.
109. Omede, P., Boccadoro, M., Gallone, G., Frieri, R., Battaglio, S., Redoglia, V. Pileri, A. (1990) MM: increased circulating lymphocytes carrying plasma cell-associated antigens as an indicator of poor survival. Blood, 76, 1375 1379.
110. Paiva, B., Vidriales, M.B., Perez, J.J., Mateo, G., Montalban, M.A., Mateos, M.V., Blade, J., Lahuerta, J.J., Orfao, A. San Miguel, J.F. (2009a) Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Haematologica, 94, 1599 1602.
111. Paiva, B., Vidriales, M.B., Mateo, G., Perez, J.J., Montalban, M.A., Sureda, A., Montejano, L., Gutierrez, N.C., Garcia de Coca, A., de las Heras, N., Mateos, M.V., Lopez-Berges, M.C., Garcia-Boyero, R., Galende, J., Hernandez, J., Palomera, L., Carrera, D., Martínez, R., de la Rubia, J., Martín, A., Gonzalez, Y., Blade, J., Lahuerta, J.J., Orfao, A. San-Miguel, J.F. GEM (Grupo Espanol de MM)/PETHEMA (Programa para el Estudio de la Terapeutica en Hemopatlas Malignas) Cooperative Study Groups. (2009b) The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients. Blood, 114, 4369 4372.
112. Pardanani, A., Witzig, T.E., Schroeder, G., McElroy, E.A., Fonseca, R., Dispenzieri, A., Lacy, M.Q., Lust, J.A., Kyle, R.A., Greipp, P.R., Gertz, M.A. Rajkumar, S.V. (2003) Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. Blood, 101, 827 830.
113. Pellat-Deceunynck, C. Bataille, R. (2004) Normal and malignant human plasma cells: proliferation, differentiation, and expansions in relation to CD45 expression. Blood Cells Molecules and Disease, 32, 293 301.
114. Pellat-Deceunynck, C., Bataille, R., Robillard, N., Harousseau, J.L., Rapp, M.J., Juge-Morineau, N., Wijdenes, J. Amiot, M. (1994) Expression of CD28 and CD40 in human myeloma Cells: a comparative study with normal plasma cells. Blood, 15, 2597 2603.
115. Pellat-Deceunynck, C., Barillé, S., Puthier, D., Rapp, M.J., Harousseau, J.L., Bataille, R. Amiot, M. (1995) Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization. Cancer Research, 55, 3647 3653.
116. Pellat-Deceunynck, C., Barille, S., Jego, G., Puthier, D., Robillard, N., Pineau, D., Rapp, M.J., Harousseau, J.L., Amiot, M. Bataille, R. (1998) The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of MM. Leukemia, 12, 1977 1982.
117. Perfetti, V., Casarini, S., Palladini, G., Vignarelli, M.C., Klersy, C., Diegoli, M., Ascari, E. Merlini, G. (2002) Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment. Blood, 100, 948 953.
118. Persona, E.P., Vidriales, M.B., Mateo, G., García-Sanz, R., Mateos, M.V., de Coca, A.G., Galende, J., Martín-Nuñez, G., Alonso, J.M., de Las Heras, N., Hernández, J.M., Martín, A., López-Berges, C., Orfao, A. San Miguel, J.F. (2007) New criteria to identify risk of progression in monoclonal gammopathy ofuncertain significance and smoldering MM based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood, 110, 2586 2592.
119. Podar, K., Chauhan, D. Anderson, K.C. (2009) Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia, 23, 10 24.
120. Qiang, Y.W., Chen, Y., Stephens, O., Brown, N., Chen, B., Epstein, J., Barlogie, B. Shaughnessy, Jr., J.D. (2008) Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in MM. Blood, 112, 196 207.
121. Rajkumar, S.V. (2005) MGUS and smoldering MM: update on pathogenesis, natural history, and management. Hematology/the Education Program of the American Society of Hematology, 2005, 340 345.
122. Rajkumar, S.V., Mesa, R.A., Fonseca, R., Schroeder, G., Plevak, M.F., Dispenzieri, A., Lacy, M.Q., Lust, J.A., Witzig, T.E., Gertz, M.A., Kyle, R.A., Russell, S.J. Greipp, P.R. (2002) Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, MM, and primary amyloidosis. Clinical Cancer Research, 8, 2210 2216.
123. Ranheim, T.S., Edelman, G.M. Cunningham, B.A. (1996) Homophilic adhesion mediated by the neural cell adhesion molecule involves multiple immunoglobulin domains. Proceedings of the National Academy of Sciences of the United States of America, 93, 4071 4075.
124. Rasmussen, T. (2001) The presence of circulating clonal CD19+ cells in MM. Leukemia and Lymphoma, 42, 1359 1366.
125. Rasmussen, T., Kastrup, J., Knudsen, L.M. Johnsen, H.E. (1999) High numbers of clonal CD19+ cells in the peripheral blood of a patient with multiple myeloma. British Journal of Haematology, 105, 265 267.
126. Rawstron, A.C., Orfao, A., Beksac, M., Bezdickova, L., Brooimans, R.A., Bumbea, H., Dalva, K., Fuhler, G., Gratama, J., Hose, D., Kovarova, L., Lioznov, M., Mateo, G., Morilla, R., Mylin, A.K., Omede, P., Pellat-Deceunynck, C., Perez Andres, M., Petrucci, M., Ruggeri, M., Rymkiewicz, G., Schmitz, A., Schreder, M., Seynaeve, C., Spacek, M., de Tute, R.M., Van Valckenborgh, E., Weston-Bell, N., Owen, R.G., San Miguel, J.F., Sonneveld, P. Johnsen, H.E. (2008) Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica, 93, 431 438.
127. Robillard, N., Jego, G., Pellat-Deceunynck, C., Pineau, D., Puthier, D., Mellerin, M.P., Barillé, S., Rapp, M.J., Harousseau, J.L., Amiot, M. Bataille, R. (1998) CD28, a marker associated with tumoral expansion in MM. Clinical Cancer Research, 4, 1521 1526.
128. Robillard, N., Avet- Loiseau, H., Garand, R., Moreau, P., Pineau, D., Rapp, M.J., Harousseau, J.L. Bataille, R. (2003) CD20 is associated with a small
129. Roldan, E., Scott, G. Ryan, D.H. (1992) VLA-4 fibronectin interactio is required for the terminal differentiation of human bone marrow cells capable of spontaneous and high rate immunoglobulin secretion. Journal of Experimental Medicine, 175, 1739 1747.
130. Roodman, G.D. (2002) Role of the bone marrow microenvironment in MM. Journal of Bone and Mineral Research, 17, 1921 1925.
131. Rossi, J.F., Chappard, D., Marcelli, C., Laplante, J., Commes, T., Baldet, P., Janbon, C., Jourdan, J., Alexandre, C. Bataille, R. (1990) Micro-osteoclast resorption as a characteristic feature of B-cell malignancies other than MM. British Journal of Haematology, 76, 469 475.
132. Rottenburger, C., Kiel, K., Bo sing, T. Cremer, F.W. (1999) Clonotypic CD20+ and CD19+ B cells in peripheral blood of patients with MM post high-dose therapy and peripheral blood stem cell transplantation. British Journal of Haematology, 106, 545 552. (Pubitemid 29450687)
133. Rudd, C.E., Janssen, O., Cai, Y.C., da Silva, A.J., Raab, M. Prasad, K.V. (1994) Two-step TCR CD3-CD4 and CD28 signaling in T cells: SH2/SH3 domains, protein tyrosine and lipid kinases. Immunology Today, 15, 225 234.
134. Rutishauser, U., Acheson, A., Hall, A.K., Mann, D.M. Sunshine, J. (1988) The neural cell adhesion molecule (NCAM) as a regulator of cell-cell interactions. Science, 240, 53 57.
135. Sahara, N., Takeshita, A., Shigeno, K., Fujisawa, S., Takeshita, K., Naito, K., Ihara, M., Ono, T., Tamashima, S., Nara, K., Ohnishi, K. Ohno, R. (2002) Clinicopathological and prognostic characteristics of CD56-negative MM. British Journal of Haematology, 117, 882 885.
136. Sahara, N., Ohnishi, K., Sugimoto, Y., Kobayashi, M., Takeshita, K., Shigeno, K., Nakamura, S., Naito, K., Tamashima, S., Nara, K., Tobita, T., Takeshita, A. Ohno, R. (2006) Clinicopathological and prognostic characteristics of CD33-positive MM. European Journal of Haematology, 77, 14 18.
137. San Miguel, J.F., Caballaro, M.D., Gonzalez, M., Moro, M.J., Hemandez, J.M., Ortega, F., Jiminez, R., Guerras, L., Romero, M. Casanova, F. (1986) Immunological phenotype of neoplasmas invologving the B cell in the step of differentiation. British Journal of Haematology, 62, 75 83.
138. Sarasquete, M.E., Garcia-Sanz, R., Gonzalez, D., Martinez, J., Mateo, G., Martinez, P., Ribera, J.M., Hernandez, J.M., Lahuerta, J.J., Orfao, A., Gonzalez, M. San Miguel, J.F. (2005) Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica, 90, 1365 1372.
139. Seegmiller, A.C., Xu, Y., McKenna, R.W. Karandikar, N.J. (2007) Immunophenotypic differentiation between neoplastic plasma cells in mature B-cell lymphoma vs plasma cell myeloma. American Journal of Clinical Pathology, 127, 176 181.
140. Seidel, C., Sundan, A., Hjorth, M., Turesson, I., Dahl, I.M., Abildgaard, N., Waage, A. Borset, M. (2000) Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood, 95, 388 392.
141. Sezer, O., Heider, U., Zavrski, I. Possinger, K. (2001) Differentiation of monoclonal gammopathy of undetermined significance and MM using flow cytometric characteristics of plasma cells. Haematologica, 86, 837 843.
142. Singh, S.K., Hawkins, C., Clarke, I.D., Squire, J.A., Bayani, J., Hide, T., Henkelman, R.M., Cusimano, M.D. Dirks, P.B. (2004) Identification of human brain tumour initiating cells. Nature, 432, 396 401.
143. Smock, K.J., Perkins, S.L. Bahler, D.W. (2007) Quantitation of plasma cells in bone marrow aspirates by flow cytometric analysis compared with morphologic assessment. Archives of Pathology & Laboratory Medicine, 131, 951 955.
144. Stone, M.J. (1990) Amyloidosis: a final common pathway for protein deposition in tissues. Blood, 75, 531 545.
145. von Strandmann, E.P., Hansen, H.P., Reiners, K.S., Schnell, R., Borchmann, P., Merkert, S., Simhadri, V.R., Draube, A., Reiser, M., Purr, I., Hallek, M. Engert, A. (2006) A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood, 107, 1955 1962.
146. Tassone, P., Goldmacher, V.S., Neri, P., Gozzini, A., Shammas, M.A., Whiteman, K.R., Hylander-Gans, L.L., Carrasco, D.R., Hideshima, T., Shringarpure, R., Shi, J., Allam, C.K., Wijdenes, J., Venuta, S., Munshi, N.C. Anderson, K.C. (2004) Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood, 104, 3688 3696.
147. Terpos, E., Sezer, O., Croucher, P. Dimopoulos, M.A. (2007) Myeloma bone disease and proteasome inhibition therapies. Blood, 110, 1098 1104.
148. Terstappen, L.W., Johnsen, S., Segers-Nolter, I.M. Loken, M.R. (1990) Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry. Blood, 76, 1739 1747.
149. Thomas, M.L. (1989) The leukocyte common antigen family. Annual Review of Immunology, 7, 339 369.
150. Treon, S.P., Pilarski, L.M., Belch, A.R., Kelliher, A., Preffer, F.I., Shima, Y., Mitsiades, C.S., Mitsiades, N.S., Szczepek, A.J., Ellman, L., Harmon, D., Grossbard, M.L. Anderson, K.C. (2002) CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. Journal of Immunotherapy, 25, 72 81.
151. Trowbridge, I.S. Thomas, M.L. (1994) CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development. Annual Review of Immunology, 12, 85 116.
152. Uckun, F.M. (1990) Regulation of human B-cell ontogeny. Blood, 76, 1908 1923.
153. Van Camp, B., Durie, B.G., Spier, C., De Waele, M., Van Riet, I., Vela, E., Frutiger, Y., Richter, L. Grogan, T.M. (1990) Plasma cells in MM express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood, 76, 377 382.
154. Van Lier, R.A., Borst, J., Vroom, T.M., Klein, H., Van Mourik, P., Zeijlemaker, W.P. Melief, C.J. (1987) Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen. Journal of Immunology, 139, 1589 1596.
155. Vescio, R.A., Hong, C.H., Cao, J., Kim, A., Schiller, G.J., Lichtenstein, A.K., Berenson, R.J. Berenson, J.R. (1994) The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma. Blood, 84, 3283 3290.
156. Wagner, J.E., Collins, D., Fuller, S., Schain, L.R., Berson, A.E., Almici, C., Hall, M.A., Chen, K.E., Okarma, T.B. Lebkowski, J.S. (1995) Isolation of small, primitive human hematopoietic stem cells: distribution of cell surface cytokine receptors and growth in SCID-Hu mice. Blood, 86, 512 523.
157. Walsh, F.S. Doherty, P. (1997) Neural cell adhesion molecules of the immunoglobulin superfamily: role in axon growth and guidance. Annual Review of Cell and Developmental Biology, 13, 425 456.
158. Weiss, M.B., Verma, P., Abadie, J., Howard, R. Kuehl, M. (2008) A pre- existing plasma cell disorder occurs in most patients with MM. Blood, 112, abstract no: 1693.
159. Witzig, T.E., Dhodapkar, M.V., Kyle, R.A. Greipp, P.R. (1993) Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with MM. Cancer, 72, 108 113.
160. Witzig, T.E., Timm, M., Larson, D., Therneau, T. Greipp, P.R. (1999) Measurement of apoptosis and proliferation of bone marrow plasma cells in patinet with plasma cell proliferative disorders. British Journal of Haematology, 104, 131 137.
161. Yoshida, T., Matsuda, M., Katoh, N., Tazawa, K., Shimojima, Y., Gono, T., Ishii, W., Nakazawa, Y., Sakashita, K., Koike, K., Yamada, T. Ikeda, S. (2008) Long-term follow-up of plasma cells in bone marrow and serum free light chains in primary systemic AL amyloidosis. Internal Medicine, 47, 1783 1790.
162. Yu, Q., Toole, B.P. Stamenkovic, I. (1997) Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. Journal of Experimental Medicine, 186, 1985 1996.
163. Zandecki, M., Facon, T., Bernardi, F., Izydorczyk, V., Dupond, L., Francois, M., Reade, R., Iaru, T., Bauters, F. Cosson, A. (1995) CD19 and immunophenotype of bone marrow plasma cells in monoclonal gammopathy of undetermined significance. Journal of Clinical Pathology, 48, 548 552.
164. Zarrabi, M.H., Stark, R.S., Kane, P., Dannaher, C.L. Chandor, S. (1981) IgM myeloma, a distinct entity in the spectrum of B-cell neoplasia. American Journal of Clinical Pathology, 75, 1 10.
165. Zeleznik-Le, N.J. Metzgar, R.S. (1989) Expression of CD9 antigenon normal activated human B cells. Cellular Immunology, 123, 70 82.
166. Zhan, F., Hardin, J., Bumm, K., Bumm, K., Zheng, M., Tian, E., Sanderson, R., Yang, Y., Wilson, C., Zangari, M., Anaissie, E., Morris, C., Muwalla, F., van Rhee, F., Fassas, A., Crowley, J., Tricot, G., Barlogie, B. Shaughnessy, Jr., J. (2003) Global gene expression profiling of MM, monoclonal gammopathy of undetermined significance and normal bone marrow plasma cells. Blood, 99, 1745 1757.
167. Zhang, X.G., Gaillard, J.P., Robillard, N., Lu, Z.Y., Gu, Z.J., Jourdan, M., Boiron, J.M., Bataille, R. Klein, B. (1994) Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in multiple myeloma. Blood, 83, 3654 3663.
168. Zhou, P., Comenzo, R.L., Olshen, A.B., Bonvini, E., Koenig, S., Maslak, P.G., Fleisher, M., Hoffman, J., Jhanwar, S., Young, J.W., Nimer, S.D. Boruchov, A.M. (2008) CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy. Blood, 111, 3403 3406.
169. Zojer, N., Schuster-Kolbe, J., Assmann, I., Ackermann, J., Strasser, K., Hübl, W., Drach, J. Ludwig, H. (2001) Chromosomal aberrations are shared by malignant plasma cells and a small fraction of circulating CD19+ cells in patients with myeloma and monoclonal gammopathy of undetermined significance. British Journal of Haematology, 117, 852 859.
170. Zola, H. (1987) The surface antigens of human B lymphocytes. Immunology Today, 8, 308 315.